Viatris Inc.
VTRS Healthcare Drug Manufacturers Specialty & Generic
Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue grew 4.88%, EPS fell 2,464.1%, free cash flow grew 101.1% and total debt fell 18.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years.
Follow VTRS
Viatris Inc. (VTRS) Return on equity
Viatris Inc.'s return on equity over the twelve months to 30 June 2026 was −2.75%, up 18.3 percentage points from fiscal 2025 (−21.1%). Over the past ten years it has ranged from −21.1% (fiscal 2025) to 13.0% (fiscal 2015) — the current reading is the lowest in ten years. That is below the Drug Manufacturers Specialty & Generic industry median of −0.40% and above the Healthcare sector median of −31.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −21.1% | (17.84) |
| FY2024 | −3.24% | (3.50) |
| FY2023 | 0.26% | (9.74) |
| FY2022 | 10.0% | 15.84 |
| FY2021 | −5.84% | (1.99) |
| FY2020 | −3.85% | (3.99) |
| FY2019 | 0.14% | (2.63) |
| FY2018 | 2.77% | (2.93) |
| FY2017 | 5.70% | 1.10 |
| FY2016 | 4.60% | (8.40) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ZTS Zoetis Inc. compare | 64.9% |
| NBIX Neurocrine Biosciences, Inc. compare | 22.1% |
| UTHR United Therapeutics Corporation compare | 19.3% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 9.69% |
| RDY Dr. Reddy's Laboratories Ltd compare | 8.21% |
| TAK Takeda Pharmaceutical Co. compare | 4.42% |
| HLN Haleon PLC Sponsored ADR compare | 0.00% |
| VTRS Viatris Inc. | −2.75% |
| ELAN Elanco Animal Health Incorporated compare | −2.98% |
| Drug Manufacturers Specialty & Generic industry median | −0.40% |
| Healthcare sector median | −31.3% |
| Market median | 1.35% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on VTRS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement